OA10271A - Multiple branch peptide constructions for use against hiv - Google Patents

Multiple branch peptide constructions for use against hiv Download PDF

Info

Publication number: OA10271A
Authority: OA; OAPI
Prior art keywords: hiv; mbpc; mbpcs; peptide; peptides
Prior art date: 1993-09-13

Application number

OA60794A

Other languages

English (en)

Inventor

Jean Marc Sabatier

Original Assignee

Armel Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-09-13

Filing date

1996-03-13

Publication date

1997-10-07

1993-09-13 Priority claimed from GB939318901A external-priority patent/GB9318901D0/en

1996-03-13 Application filed by Armel Sa filed Critical Armel Sa

1997-10-07 Publication of OA10271A publication Critical patent/OA10271A/en

Links

108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 81
238000010276 construction Methods 0.000 title claims abstract description 17
102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 42
241000725303 Human immunodeficiency virus Species 0.000 claims description 25
239000011159 matrix material Substances 0.000 claims description 21
125000000539 amino acid group Chemical group 0.000 claims description 14
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 12
230000002401 inhibitory effect Effects 0.000 claims description 8
150000008574 D-amino acids Chemical group 0.000 claims description 5
239000002253 acid Substances 0.000 claims description 5
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 5
230000002163 immunogen Effects 0.000 claims description 4
125000006850 spacer group Chemical group 0.000 claims description 2
VJLLLMIZEJJZTE-VNQXHBPZSA-N HexCer(d18:1/16:0) Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)\C=C\CCCCCCCCCCCCC)COC1OC(CO)C(O)C(O)C1O VJLLLMIZEJJZTE-VNQXHBPZSA-N 0.000 claims 1
125000003275 alpha amino acid group Chemical group 0.000 claims 1
241000713772 Human immunodeficiency virus 1 Species 0.000 abstract description 45
208000031886 HIV Infections Diseases 0.000 abstract description 33
150000001413 amino acids Chemical class 0.000 abstract description 18
241000713340 Human immunodeficiency virus 2 Species 0.000 abstract description 16
108020003175 receptors Proteins 0.000 abstract description 14
210000002540 macrophage Anatomy 0.000 abstract description 13
210000004698 lymphocyte Anatomy 0.000 abstract description 9
108010041397 CD4 Antigens Proteins 0.000 abstract description 7
230000004927 fusion Effects 0.000 abstract description 7
230000034217 membrane fusion Effects 0.000 abstract description 6
108091035707 Consensus sequence Proteins 0.000 abstract description 5
238000000338 in vitro Methods 0.000 abstract description 5
210000001072 colon Anatomy 0.000 abstract description 4
108010003533 Viral Envelope Proteins Proteins 0.000 abstract description 3
210000000170 cell membrane Anatomy 0.000 abstract 3
210000002919 epithelial cell Anatomy 0.000 abstract 1
230000001790 virustatic effect Effects 0.000 abstract 1
208000002839 megalencephalic leukoencephalopathy with subcortical cysts Diseases 0.000 description 56
238000004242 micellar liquid chromatography Methods 0.000 description 56
210000004027 cell Anatomy 0.000 description 54
241000283973 Oryctolagus cuniculus Species 0.000 description 27
208000015181 infectious disease Diseases 0.000 description 27
230000000694 effects Effects 0.000 description 23
102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 18
210000005105 peripheral blood lymphocyte Anatomy 0.000 description 18
229940024606 amino acid Drugs 0.000 description 15
235000001014 amino acid Nutrition 0.000 description 14
239000000427 antigen Substances 0.000 description 13
102000036639 antigens Human genes 0.000 description 13
108091007433 antigens Proteins 0.000 description 13
230000015572 biosynthetic process Effects 0.000 description 13
102000005962 receptors Human genes 0.000 description 12
DDOVBCWVTOHGCU-QMXMISKISA-N n-[(e,2s,3r)-3-hydroxy-1-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxynonadec-4-en-2-yl]octadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)\C=C\CCCCCCCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O DDOVBCWVTOHGCU-QMXMISKISA-N 0.000 description 11
230000005764 inhibitory process Effects 0.000 description 10
238000000034 method Methods 0.000 description 9
239000000178 monomer Substances 0.000 description 9
230000001225 therapeutic effect Effects 0.000 description 9
208000037357 HIV infectious disease Diseases 0.000 description 8
241000699666 Mus <mouse, genus> Species 0.000 description 8
UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 8
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 8
230000009257 reactivity Effects 0.000 description 8
238000012360 testing method Methods 0.000 description 8
231100000331 toxic Toxicity 0.000 description 8
230000002588 toxic effect Effects 0.000 description 8
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 7
241000700605 Viruses Species 0.000 description 7
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 7
238000010790 dilution Methods 0.000 description 7
239000012895 dilution Substances 0.000 description 7
230000003612 virological effect Effects 0.000 description 7
102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 6
241000699670 Mus sp. Species 0.000 description 6
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 6
238000010348 incorporation Methods 0.000 description 6
238000004519 manufacturing process Methods 0.000 description 6
101710121417 Envelope glycoprotein Proteins 0.000 description 5
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
239000004472 Lysine Substances 0.000 description 5
239000012980 RPMI-1640 medium Substances 0.000 description 5
244000309466 calf Species 0.000 description 5
230000000875 corresponding effect Effects 0.000 description 5
238000002474 experimental method Methods 0.000 description 5
230000003993 interaction Effects 0.000 description 5
239000003226 mitogen Substances 0.000 description 5
101100260020 Caenorhabditis elegans mls-1 gene Proteins 0.000 description 4
238000002965 ELISA Methods 0.000 description 4
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 4
108010047620 Phytohemagglutinins Proteins 0.000 description 4
125000003277 amino group Chemical group 0.000 description 4
229940000635 beta-alanine Drugs 0.000 description 4
230000000903 blocking effect Effects 0.000 description 4
230000007910 cell fusion Effects 0.000 description 4
239000012228 culture supernatant Substances 0.000 description 4
238000007499 fusion processing Methods 0.000 description 4
230000005847 immunogenicity Effects 0.000 description 4
238000001727 in vivo Methods 0.000 description 4
229960000310 isoleucine Drugs 0.000 description 4
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 4
238000005259 measurement Methods 0.000 description 4
239000002609 medium Substances 0.000 description 4
230000001885 phytohemagglutinin Effects 0.000 description 4
230000004044 response Effects 0.000 description 4
231100000419 toxicity Toxicity 0.000 description 4
230000001988 toxicity Effects 0.000 description 4
238000005406 washing Methods 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
238000000134 MTT assay Methods 0.000 description 3
231100000002 MTT assay Toxicity 0.000 description 3
108091005804 Peptidases Proteins 0.000 description 3
230000005875 antibody response Effects 0.000 description 3
230000000890 antigenic effect Effects 0.000 description 3
230000008901 benefit Effects 0.000 description 3
238000004113 cell culture Methods 0.000 description 3
230000001413 cellular effect Effects 0.000 description 3
230000000120 cytopathologic effect Effects 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
230000003287 optical effect Effects 0.000 description 3
230000008569 process Effects 0.000 description 3
108010043277 recombinant soluble CD4 Proteins 0.000 description 3
229960005486 vaccine Drugs 0.000 description 3
MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 2
208000030507 AIDS Diseases 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
101100112111 Caenorhabditis elegans cand-1 gene Proteins 0.000 description 2
101150117151 Cand2 gene Proteins 0.000 description 2
DXENDDMPDZMHSQ-UHFFFAOYSA-N Candinine Chemical compound C12=NC3=CC=CC=C3C(=O)N1C1=CC=CC=C1C2=C1C(=O)C2=CC=CC=C2N1 DXENDDMPDZMHSQ-UHFFFAOYSA-N 0.000 description 2
241000282693 Cercopithecidae Species 0.000 description 2
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
150000008575 L-amino acids Chemical group 0.000 description 2
102000035195 Peptidases Human genes 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
241000282898 Sus scrofa Species 0.000 description 2
-1 acrylic ester Chemical class 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
230000000840 anti-viral effect Effects 0.000 description 2
238000003556 assay Methods 0.000 description 2
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
235000009508 confectionery Nutrition 0.000 description 2
230000002596 correlated effect Effects 0.000 description 2
125000004122 cyclic group Chemical group 0.000 description 2
201000010099 disease Diseases 0.000 description 2
238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 2
125000000524 functional group Chemical group 0.000 description 2
210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 2
239000003550 marker Substances 0.000 description 2
239000000203 mixture Substances 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
238000006386 neutralization reaction Methods 0.000 description 2
230000003472 neutralizing effect Effects 0.000 description 2
229940049954 penicillin Drugs 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
235000019833 protease Nutrition 0.000 description 2
239000011347 resin Substances 0.000 description 2
229920005989 resin Polymers 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 1
HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
101100408068 Amanita phalloides PHA1 gene Proteins 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
DXENDDMPDZMHSQ-FMQUCBEESA-N Candidine Natural products C12=NC3=CC=CC=C3C(=O)N1C1=CC=CC=C1/C2=C1/C(=O)C2=CC=CC=C2N1 DXENDDMPDZMHSQ-FMQUCBEESA-N 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
108020004414 DNA Proteins 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
229930186217 Glycolipid Natural products 0.000 description 1
108010083930 HIV Receptors Proteins 0.000 description 1
102000006481 HIV Receptors Human genes 0.000 description 1
101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 description 1
102000000588 Interleukin-2 Human genes 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
241000282553 Macaca Species 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
241000283977 Oryctolagus Species 0.000 description 1
102000007079 Peptide Fragments Human genes 0.000 description 1
108010033276 Peptide Fragments Proteins 0.000 description 1
102000003992 Peroxidases Human genes 0.000 description 1
208000037581 Persistent Infection Diseases 0.000 description 1
239000004365 Protease Substances 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
108070000030 Viral receptors Proteins 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
230000003141 anti-fusion Effects 0.000 description 1
230000036436 anti-hiv Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
230000008275 binding mechanism Effects 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
150000003857 carboxamides Chemical class 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000005018 casein Substances 0.000 description 1
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
235000021240 caseins Nutrition 0.000 description 1
230000003833 cell viability Effects 0.000 description 1
238000003570 cell viability assay Methods 0.000 description 1
230000008859 change Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000003501 co-culture Methods 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
230000002354 daily effect Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
239000000412 dendrimer Substances 0.000 description 1
229920000736 dendritic polymer Polymers 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
230000009881 electrostatic interaction Effects 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
229930182830 galactose Natural products 0.000 description 1
125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
229910000040 hydrogen fluoride Inorganic materials 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
230000008105 immune reaction Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
208000033065 inborn errors of immunity Diseases 0.000 description 1
238000011534 incubation Methods 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
239000002054 inoculum Substances 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
231100001231 less toxic Toxicity 0.000 description 1
230000007774 longterm Effects 0.000 description 1
210000004779 membrane envelope Anatomy 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
238000009448 modified atmosphere packaging Methods 0.000 description 1
235000019837 monoammonium phosphate Nutrition 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
210000005087 mononuclear cell Anatomy 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
230000037361 pathway Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
208000028529 primary immunodeficiency disease Diseases 0.000 description 1
235000019419 proteases Nutrition 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
208000015476 pseudohypoaldosteronism type 1 Diseases 0.000 description 1
238000000746 purification Methods 0.000 description 1
238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
238000002976 reverse transcriptase assay Methods 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
230000001568 sexual effect Effects 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
238000010532 solid phase synthesis reaction Methods 0.000 description 1
238000010186 staining Methods 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000009897 systematic effect Effects 0.000 description 1
238000004809 thin layer chromatography Methods 0.000 description 1
125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
238000001262 western blot Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Virology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Gastroenterology & Hepatology (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

OA60794A 1993-09-13 1996-03-13 Multiple branch peptide constructions for use against hiv OA10271A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB939318901A GB9318901D0 (en)	1993-09-13	1993-09-13	Multiple branch peptide construction
US08/260,086 US5622933A (en)	1993-09-13	1994-06-15	Multiple branch peptide constructions for use against HIV

Publications (1)

Publication Number	Publication Date
OA10271A true OA10271A (en)	1997-10-07

Family

ID=26303508

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA60794A OA10271A (en)	1993-09-13	1996-03-13	Multiple branch peptide constructions for use against hiv

Country Status (15)

Country	Link
EP (1)	EP0719281B1 (de)
CN (1)	CN1130911A (de)
AP (1)	AP502A (de)
AT (1)	ATE183201T1 (de)
AU (1)	AU7619694A (de)
BR (1)	BR9407530A (de)
DE (1)	DE69420042T2 (de)
DK (1)	DK0719281T3 (de)
ES (1)	ES2137378T3 (de)
GR (1)	GR3031367T3 (de)
HU (1)	HUT75092A (de)
IL (1)	IL110929A0 (de)
OA (1)	OA10271A (de)
PL (1)	PL313520A1 (de)
WO (1)	WO1995007929A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2719049B1 (fr) *	1994-04-22	1996-06-14	Pasteur Institut	Multireprésentation d'un analogue peptidique du substrat de la DPPIV, notamment de type KPR, afin d'inhiber l'entrée du HIV dans les cellules.
GB9627114D0 (en) *	1996-12-31	1997-02-19	Centre Nat Rech Scient	Multiple branch peptide constructions
GB9727424D0 (en) *	1997-12-31	1998-02-25	Armel Sa	Liposomes containing multiple branch peptide constructions for use against human immunodeficiency virus
CN1100564C (zh) *	2001-08-29	2003-02-05	周根发	用于治疗hiv感染的药物、其组合物及其用途
AU2004240765B2 (en) *	2003-05-20	2009-03-19	Cellpep Sa	Modified antiviral peptides with increased activity and cell membrane affinity
US7604804B2 (en)	2004-02-09	2009-10-20	University Of Maryland Biotechnology Institute	Enhancing anti-HIV efficiency through multivalent inhibitors targeting oligomeric gp120
JP2010537997A (ja) *	2007-08-27	2010-12-09	マサチューセッツインスティテュートオブテクノロジー	二機能性ポリマーに結合させたインフルエンザウイルス阻害剤
CN102532280A (zh) *	2010-12-08	2012-07-04	吉林大学	一种hiv免疫原及其制备
CN104415739A (zh) *	2013-08-28	2015-03-18	天津市阳权医疗器械有限公司	苯乙烯-二乙烯苯医用树脂的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1341285C (en) *	1988-02-12	2001-08-14	Chang Yi Wang	Synthetic peptides for the detection of antibodies to hiv gp120 envelope protein for diagnosis of aids and pre-aids conditions and as vaccines
JPH05508165A (ja) *	1991-04-02	1993-11-18	アルバート・アインシュタイン・カレッジ・オブ・メディシン・オブ・イェシーバ・ユニバーシティー	Ｈｉｖの処置および予防用ワクチン
WO1993003766A1 (en) *	1991-08-13	1993-03-04	Repligen Corporation	Multiple antigen peptides for use as hiv vaccines

1994
- 1994-09-12 IL IL11092994A patent/IL110929A0/xx unknown
- 1994-09-13 AU AU76196/94A patent/AU7619694A/en not_active Abandoned
- 1994-09-13 ES ES94926312T patent/ES2137378T3/es not_active Expired - Lifetime
- 1994-09-13 AP APAP/P/1994/000680A patent/AP502A/en active
- 1994-09-13 CN CN94193388.1A patent/CN1130911A/zh active Pending
- 1994-09-13 HU HU9600594A patent/HUT75092A/hu unknown
- 1994-09-13 WO PCT/GB1994/001992 patent/WO1995007929A1/en not_active Ceased
- 1994-09-13 BR BR9407530A patent/BR9407530A/pt not_active Application Discontinuation
- 1994-09-13 DK DK94926312T patent/DK0719281T3/da active
- 1994-09-13 EP EP94926312A patent/EP0719281B1/de not_active Expired - Lifetime
- 1994-09-13 DE DE69420042T patent/DE69420042T2/de not_active Expired - Fee Related
- 1994-09-13 AT AT94926312T patent/ATE183201T1/de not_active IP Right Cessation
- 1994-09-13 PL PL94313520A patent/PL313520A1/xx unknown
1996
- 1996-03-13 OA OA60794A patent/OA10271A/en unknown
1999
- 1999-09-29 GR GR990402461T patent/GR3031367T3/el unknown

Also Published As

Publication number	Publication date
AP9400680A0 (en)	1994-10-31
EP0719281A1 (de)	1996-07-03
PL313520A1 (en)	1996-07-08
BR9407530A (pt)	1997-08-26
EP0719281B1 (de)	1999-08-11
IL110929A0 (en)	1994-11-28
ES2137378T3 (es)	1999-12-16
WO1995007929A1 (en)	1995-03-23
HUT75092A (en)	1997-04-28
AU7619694A (en)	1995-04-03
HU9600594D0 (en)	1996-05-28
CN1130911A (zh)	1996-09-11
DE69420042T2 (de)	2000-04-13
DK0719281T3 (da)	2000-03-20
DE69420042D1 (de)	1999-09-16
ATE183201T1 (de)	1999-08-15
GR3031367T3 (en)	2000-01-31
AP502A (en)	1996-06-07

Publication	Publication Date	Title
Grundner et al.	2005	Analysis of the neutralizing antibody response elicited in rabbits by repeated inoculation with trimeric HIV-1 envelope glycoproteins
US5639854A (en)	1997-06-17	Tandem synthetic HIV-1 peptides
US6335017B1 (en)	2002-01-01	Compositions and methods for treating viral infections
US8173767B2 (en)	2012-05-08	Synthetic peptide vaccines for HIV: the CBD epitope as an effective immunogen to elicit broadly neutralizing antibodies against HIV
US7172761B2 (en)	2007-02-06	Polyvalent immunogen
US7195768B2 (en)	2007-03-27	Polyvalent immunogen
HU214439B (hu)	1998-03-30	Eljárás HIV-fertőzések kezelésére alkalmas monoklonális antitestek és peptidek, valamint ezeket tartalmazó gyógyászati készítmények és vakcinák előállítására
AP502A (en)	1996-06-07	Multiple branch peptide constructions for use against HIV.
US5622933A (en)	1997-04-22	Multiple branch peptide constructions for use against HIV
EP0762895B1 (de)	2002-08-07	Synthetischer impfstoff zum schutz gegen infektionen mit dem menschlichen immunschwächevirus
US5346989A (en)	1994-09-13	Peptides for use in induction of T cell activation against HIV-1
JPH07505878A (ja)	1995-06-29	Ｈｉｖエンベロープ糖タンパク質から誘導された合成ポリペプチド
Hosmalin et al.	1992	Immunization with soluble protein-pulsed spleen cells induces class I-restricted cytotoxic T lymphocytes that recognize immunodominant epitopic peptides from Plasmodium falciparum and HIV-1
EP0950063B1 (de)	2003-03-26	Vielfältig verzweigte peptidkonstruktionen
CA2171531C (en)	2005-11-22	Multiple branch peptide constructions for use against hiv
JP3725899B6 (ja)	2006-02-22	Ｈｉｖに対して使用するための多分岐ペプチド構築物
US7285621B2 (en)	2007-10-23	Multiple branch peptide construction
EP0328390A2 (de)	1989-08-16	Peptidbehandlung von hartnäckigen Infektionskrankheiten
JPH07145078A (ja)	1995-06-06	エイズワクチン
JPH08231423A (ja)	1996-09-10	エイズワクチン
HK1072264B (en)	2011-08-26	Synthetic peptide vaccines for hiv: the cbd epitope as an effective immunogen to elicit broadly neutralizing antibodies against hiv
AU2006200455A1 (en)	2006-02-23	Compositions and methods for treating viral infections